BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and
markets products in the field of regenerative medicine, announced that
Chief Executive Officer Michael D. West, PhD will give the keynote
address at the MSC
2013 Adult Stem Cell Therapy & Regenerative Medicine conference
on Monday, August 19, 2013, at 12:15 p.m. EDT in Cleveland, Ohio. Dr.
West will discuss the potential use of embryonic mesenchymal progenitor
cells, generated using BioTime’s PureStem™technology,
in regenerative medicine and will contrast the properties of those cells
with adult-derived mesenchymal stem cells. He will also discuss how
those cells can be utilized in the search for genes potentially useful
in induced tissue regeneration (iTR). The presentation will be available
on BioTime’s website at www.biotimeinc.com/scientific-presentations.
MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine, August 19-21,
2013, is being held at the Cleveland Marriott Downtown at Key Center and
is presented by Case Western Reserve University and the National Center
for Regenerative Medicine.
About BioTime, Inc
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime’s focus is on pluripotent stem cell technology based on
human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”)
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime’s
therapeutic and research products include a wide array of proprietary PureStem™
progenitors, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (a HyStem®
product) as a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. In addition,
BioTime has developed Hextend®, a blood
plasma volume expander for use in surgery, emergency trauma treatment
and other applications. Hextend® is manufactured and
distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
CheilJedang Corporation under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research,
therapeutic, and diagnostic use through its subsidiaries:
-
OncoCyte Corporation is developing products and technologies to
diagnose and treat cancer.
-
ES Cell International Pte Ltd., a Singapore private limited company,
develops hES products for research use.
-
OrthoCyte Corporation is developing therapies to treat orthopedic
disorders, diseases and injuries.
-
ReCyte Therapeutics, Inc. is developing therapies to treat a variety
of blood and lymphatic vascular disorders, as well as products for
research using iPS and other cell reprogramming technology.
-
Cell Cure Neurosciences Ltd. (“Cell Cure Neurosciences”) is an
Israel-based biotechnology company focused on developing stem
cell-based therapies for retinal and neurological degenerative
diseases. Its lead product is OpRegen® for the
treatment of macular degeneration.
-
LifeMap Sciences, Inc. (“LifeMap Sciences”) markets, sells and
distributes GeneCards®, the leading human
gene database, the leading human gene database, as part of an
integrated database suite that also includes the LifeMap Discovery™
database of embryonic development, stem cell research and regenerative
medicine, and MalaCards, the human disease database. LifeMap
Sciences also markets BioTime research products and PanDaTox,
an innovative, recently developed, searchable database that can aid in
the discovery of new antibiotics and biotechnologically beneficial
products.
-
Asterias Biotherapeutics, Inc. is a new subsidiary being used to
acquire the stem cell assets of Geron Corporation, including patents
and other intellectual property, biological materials, reagents and
equipment for the development of new therapeutic products for
regenerative medicine.
Additional information about BioTime can be found on the web at www.biotimeinc.com.
Forward-Looking Statements
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
Copyright Business Wire 2013